As active and enthusiastic members of the Open Systems Pharmacology (OSP) management team and provider of PBPK-QSP services, we would like to guide your attention to this recent publication, in CPT: Pharmacometrics & Systems Pharmacology, summarizing the principal ideas, organization and functionalities of the OSP platforms (PK-Sim/MoBi) and community.
Please note that WCoP2020 and this workshop has been postponed due to the international COVID-19 outbreak. More information available at the WCoP official home page.
Going to WCoP 2020 in Cape Town?
Join the 1-day hands-on workshop “Open source PBPK modelling with the OSPSuite (PK-Sim® & MoBi®) for MIDD” hosted by Pharmetheus and Pharmacometrics Africa.
Read more and register here.
Register soon, only limited seats available!
We are feeling grateful! Marie Olsson has joined our Finance and Admin team as Administrative Assistant. She has long experience of administration and stores management, in leading positions. She will help bring further structure and make our daily operations even more effective. See her bio here.
It is with great pleasure that we welcome Siv Jönsson to our team! Siv has been working in the pharmacokinetic, pharmacodynamic and pharmacometric areas in the pharmaceutical industry for a total of 5 years (Kabi Pharmacia, AstraZeneca), as a regulatory assessor at the Swedish Medical Products Agency for 9 years, and spent +10 years in academia as a senior lecturer and researcher dealing with methodological and applied pharmacometric projects. See her bio here.
Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.
We are glad to announce that Ida Netterberg (MIDD consultant) is returning to Pharmetheus after recently defending her PhD thesis at Uppsala University. Ida’s thesis focused on pharmacometric evaluation of biomarkers to improve treatment in oncology. See Ida’s bio here.